Kenneth C. Anderson, MD, on Multiple Myeloma: Current Treatment Approaches and Future Directions
2015 NCCN Annual Conference
Kenneth C. Anderson, MD, of Dana-Farber/Brigham and Women’s Cancer Center, discusses the incredible progress made in treating multiple myeloma, with nine therapeutic options approved in the past decade, two drugs approved this year, and a number of new options on the horizon.
Melinda Telli, MD
Melinda Telli, MD, of Stanford Cancer Institute, discusses the TNT trial for triple-negative breast cancer and the results reported at the San Antonio Breast Cancer Symposium.
Samuel M. Silver, MD, PhD, and Al B. Benson III, MD, FACP, FASCO
Samuel M. Silver, MD, PhD, of the University of Michigan Comprehensive Cancer Center, and Al B. Benson III, MD, FACP, FASCO, of Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discuss the evolution of NCCN Guidelines, which are available free online, and the components that make them effective: a multidisciplinary approach, the participation of patient advocates, consistency, and affordability of the evidence.
Gregory A. Otterson, MD
Gregory A. Otterson, MD, of The Ohio State University Comprehensive Cancer Center and the James Cancer Hospital and Solove Research Institute, discusses the evolution of lung cancer treatment from adjuvant chemotherapy to immunotherapy and the clinical trials underway.
Wui-Jin Koh, MD
Wui-Jin Koh, MD, of the Fred Hutchinson Cancer Research Center and the Seattle Cancer Care Alliance, discusses the program to adapt NCCN guidelines to regions of the world with different resource availability. The first guideline to be adapted in this way is for cervical cancer, which is prevalent in the developing world.
Mary Lou Smith, JD, MBA
Mary Lou Smith, JD, MBA, of the Research Advocacy Network, discusses, from the perspective of a patient advocate, the value of the NCCN guidelines and the impact they have made on cancer care.